Semaglutide
The gold-standard GLP-1 receptor agonist — extended half-life (~160 hrs), once-weekly dosing, and the most extensive clinical evidence base of any GLP-1 compound in research.
What Is Semaglutide?
Overview, molecular structure & mechanism
Semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist — a 31-amino acid modified peptide that mimics the endogenous incretin hormone GLP-1 with dramatically improved pharmacokinetics. Developed by Novo Nordisk, it shares ~94% structural homology with native human GLP-1 but incorporates three key molecular modifications that extend its half-life to approximately 160 hours, enabling once-weekly subcutaneous administration.[1]
Key Molecular Modifications
- Position 8: Alanine → α-aminoisobutyric acid (Aib) — protects against DPP-4 enzymatic degradation
- Position 34: Lysine → Arginine — removes an alternative acylation site
- Position 26: Acylation with a C18 fatty di-acid chain via a spacer — enables reversible albumin binding, drastically reducing renal clearance
Albumin Binding — Why It Has a 7-Day Half-Life
The C18 fatty di-acid chain at position 26 binds reversibly to serum albumin in the bloodstream. Since albumin has a half-life of ~19 days, semaglutide "hitchhikes" on albumin, escaping renal filtration and protecting against enzymatic degradation. Only a small free fraction is available to bind GLP-1 receptors at any moment — providing sustained, low-level receptor activation throughout the week.[1]
Clinical Evidence
STEP, SUSTAIN, SELECT & FLOW trial data
STEP Program — Weight Management (2021–2025)[2]
The STEP (Semaglutide Treatment Effect in People with obesity) program enrolled over 4,500 participants across 4 Phase 3 trials using 2.4 mg/week subcutaneous semaglutide.
SELECT Trial — Cardiovascular Protection (2023)[3]
The SELECT trial enrolled 17,604 adults with established CV disease but without diabetes. Semaglutide 2.4 mg/week reduced MACE by 26% vs placebo over 34 months — first GLP-1 agonist to demonstrate CV benefit in non-diabetic population.
FLOW Trial — Renal Protection (2024)[7]
FLOW demonstrated a 24% reduction in composite kidney outcome in T2D patients with chronic kidney disease.
Semaglutide vs Competing GLP-1 Agents
| Compound | Receptors | Weight Loss (Phase 3) | CV Benefit |
|---|---|---|---|
| Liraglutide 3mg (Saxenda) | GLP-1 | −5.0% | Modest (LEADER) |
| Semaglutide 2.4mg | GLP-1 | −14.9% | −26% MACE (SELECT) |
| Tirzepatide 15mg | GLP-1/GIP | −22.5% | SURPASS-CVOT pending |
| Retatrutide 12mg | GLP-1/GIP/Glucagon | −30.3% | Phase 3 ongoing |
Research Dosing Protocol
⚠ Research reference only — not medical advice
Reconstitution — 5 mg Vial
Standard Escalation Schedule (STEP Program Protocol)[2]
| Phase | Weekly Dose | Units (U-100) | Volume | Notes |
|---|---|---|---|---|
| Weeks 1–4 | 0.25 mg | 10 U | 0.10 mL | Initiation dose |
| Weeks 5–8 | 0.5 mg | 20 U | 0.20 mL | Per tolerance |
| Weeks 9–12 | 1.0 mg | 40 U | 0.40 mL | Per tolerance |
| Weeks 13–16 | 1.7 mg | 68 U | 0.68 mL | Per tolerance |
| Week 17+ | 2.4 mg | 96 U | 0.96 mL | Maintenance dose |
Administration Notes
- Route: Subcutaneous — abdomen, thigh, or upper arm
- Frequency: Once weekly, same day each week
- Half-life: ~7 days — missed doses can be taken within 5 days
- Rotation: Rotate injection sites to prevent lipodystrophy
Safety Profile & Tolerability
Phase 3 adverse event data — research reference
Semaglutide's safety profile is the most comprehensively documented of any GLP-1 agonist — over 45,000 participants across STEP, SUSTAIN, SELECT, and FLOW programs.[2,3]
Most Common Adverse Events (2.4 mg group, STEP 1)
Key Safety Notes
- GI events: transient, dose-dependent, peak during escalation
- Discontinuation rate (STEP 1): 7.0% vs 3.1% placebo
- Hypoglycemia: rare in non-diabetic subjects
- Heart rate: modest increase (+1–2 bpm)
- Thyroid C-cell: rodent signal; human relevance not established
- Pancreatitis: rare serious adverse event
Reconstitution & Storage Guide
Step-by-step lab preparation reference
Standard Reconstitution — 5 mg Vial
Step-by-Step Procedure
- Allow lyophilized vial to reach room temperature (~15 min)
- Clean rubber stoppers with 70% isopropyl alcohol
- Draw 2.0 mL of bacteriostatic water into a clean 3 mL syringe
- Inject water slowly down the side of the vial — never spray onto powder
- Gently swirl (no vortex/shake) until dissolved — clear, colorless to slightly yellow
- Discard if cloudiness or particles visible
- Label with date and store at 2–8 °C
Storage Conditions
| State | Temperature | Shelf Life | Notes |
|---|---|---|---|
| Lyophilized (powder) | −20 °C (freezer) | 18–24 months | Keep desiccated & dark |
| Lyophilized (powder) | 2–8 °C (fridge) | 3–6 months | Avoid freeze-thaw cycles |
| Reconstituted | 2–8 °C (fridge) | 28 days | Do not freeze |
Research Literature & Official Sources
Peer-reviewed studies, FDA data, clinical trials
Primary Clinical Studies
- Wilding JPH et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021;384:989-1002. (STEP 1) 🔗 NEJM
- Lincoff AM et al. "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." N Engl J Med. 2023;389:2221-2232. (SELECT) 🔗 SELECT
- Perkovic V et al. "Semaglutide and Kidney Outcomes." N Engl J Med. 2024. (FLOW) 🔗 FLOW
Pharmacology Reviews
- "Semaglutide from Bench to Bedside." PMC 2025. 🔗 PMC 2025
- FDA Prescribing Information — Ozempic/Wegovy 2025. 🔗 FDA Label
References & Footnotes
- Lau J et al. "Discovery of the Once-Weekly GLP-1 Analogue Semaglutide." J Med Chem. 2015;58(18):7370–7380. PMC review: PMC12642005
- Wilding JPH et al. STEP 1. N Engl J Med. 2021;384:989-1002. DOI
- Lincoff AM et al. SELECT. N Engl J Med. 2023;389:2221-2232. DOI
- Wadden TA et al. STEP 3. JAMA. 2021;325(14):1403-1413.
- Davies M et al. STEP 2. Lancet. 2021;397:971-984.
- Rubino DM et al. STEP 4. JAMA. 2021;325(14):1414-1425.
- Perkovic V et al. FLOW. N Engl J Med. 2024. DOI
© 2026 MVLabs.mx. For research and educational purposes only. Not intended for human consumption. Peptide Calculator · Semaglutide at MVLabs